Quantcast
Home > Quotes > HEB

Hemispherx BioPharma, Inc. Common Stock (HEB) Quote & Summary Data

HEB 
$0.22
*  
0.009
3.93%
Get HEB Alerts
*Delayed - data as of Feb. 20, 2019  -  Find a broker to begin trading HEB now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    HEB Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
Today's High / Low
$ 0.23 / $ 0.22
Share Volume
188,103
90 Day Avg. Daily Volume
294,221
Previous Close
$ 0.229
52 Week High / Low
$ 0.59 / $ 0.1521
Market Cap
10,764,670
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.15

Intraday Chart

Shares Traded

Share Volume:
188,103
90 Day Avg. Daily Volume:
294,221

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.25

Trading Range

The current last sale of $0.22 is 44.64% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.23 $ 0.59
 Low: $ 0.22 $ 0.1521

Company Description (as filed with the SEC)

Hemispherx Biopharma, Inc. and its subsidiaries (collectively, "Hemispherx", "Company", "we" or "us") are a specialty pharmaceutical company headquartered in Orlando, Florida and engaged in the development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. Our flagship products include Alferon N Injection® and the experimental therapeutic Ampligen®. Alferon N Injection® is approved for a category of STD infection, and Ampligen® represents an experimental RNA being developed for globally important viral diseases and disorders of the immune system.  ... More ...  

Research Brokers before you trade

Want to trade FX?

Analyst Info